ONCOLOGY

Data from the ongoing dose-escalation stage of a first-in-human phase 1/2 clinical study.

CRISPR-Cas9 has been used for the first time to successfully edit the latency-associated nuclear antigen (LANA) of the KSHV virus, and reduce viral episome burden in infected cells

A pooled analysis of data from SMART and START studies allows calculating the magnitude and quality of benefits of life-long antiretroviral treatment

"Site-agnostic" oral therapy for tumors with NTRK gene fusion.

A more flexible and tailored approach to trial recruitment could help 12 to 25-year-old patients by giving them access to new cancer treatments.

The establishment of a national reference centre in France with multidisciplinary committees (RCP) has markedly improved outcomes for sarcoma patients.

Oncologists should replace the Internet as a primary source of information.

Drug interactions more common with TKIs than chemotherapy.

The new review process will streamline FDA evaluation of other oncology drugs.

Early ART initiation, adherence, and screening are keys to HIV cancer risk reduction.

Aging patients with HIV require more comprehensive prostate, lung cancer screening.

Available studies were very few and of low quality.

ALK+ IMFTs demonstrate significant response to ALK inhibitor crizotinib

Phase 1 study of radioiodinated 8H9 to evaluate toxicity, pharmacokinetics, biodistribution and efficacy